10x Genomics Q4 revenue totals USD 166.03 million, up 1 percent

Reuters

Feb 13

<a href="https://laohu8.com/S/TXG">10x Genomics</a> Q4 revenue totals USD 166.03 million, up 1 percent

10x Genomics reported revenue of USD 166.03 million for the fourth quarter (Q4) of 2025, representing a 1% increase. Gross margin for the quarter was 68%, compared to 67% for the same period in the prior year. For the full year (FY) 2025, total revenue was USD 642.82 million. Products and services revenue reached USD 596.69 million in FY 2025, while license and royalty revenue totaled USD 46.14 million. The company ended the year with USD 523.4 million in cash, cash equivalents, and marketable securities, reflecting an increase of USD 130 million over the prior year. During the period, 10x Genomics CEO Serge Saxonov noted disciplined execution amid a challenging environment and highlighted strengthening business fundamentals. The company reported expanding impact from its platforms, driven by product innovations and strategic partnerships. 10x Genomics also cited positioning for growth in areas including AI-driven demand, translational research, and emerging clinical opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611970896"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611970896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611970896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611970896","market":"us","top_or_hot":-1,"title":"10x Genomics Q4 revenue totals USD 166.03 million, up 1 percent","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TXG\">10x Genomics</a> Q4 revenue totals USD 166.03 million, up 1 percent\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        10x Genomics reported revenue of USD 166.03 million for the fourth quarter (Q4) of 2025, representing a 1% increase. Gross margin for the quarter was 68%, compared to 67% for the same period in the prior year. For the full year (FY) 2025, total revenue was USD 642.82 million. Products and services revenue reached USD 596.69 million in FY 2025, while license and royalty revenue totaled USD 46.14 million. The company ended the year with USD 523.4 million in cash, cash equivalents, and marketable securities, reflecting an increase of USD 130 million over the prior year. During the period, 10x Genomics CEO Serge Saxonov noted disciplined execution amid a challenging environment and highlighted strengthening business fundamentals. The company reported expanding impact from its platforms, driven by product innovations and strategic partnerships. 10x Genomics also cited positioning for growth in areas including AI-driven demand, translational research, and emerging clinical opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10x Genomics Q4 revenue totals USD 166.03 million, up 1 percent</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10x Genomics Q4 revenue totals USD 166.03 million, up 1 percent\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TXG\">10x Genomics</a> Q4 revenue totals USD 166.03 million, up 1 percent\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        10x Genomics reported revenue of USD 166.03 million for the fourth quarter (Q4) of 2025, representing a 1% increase. Gross margin for the quarter was 68%, compared to 67% for the same period in the prior year. For the full year (FY) 2025, total revenue was USD 642.82 million. Products and services revenue reached USD 596.69 million in FY 2025, while license and royalty revenue totaled USD 46.14 million. The company ended the year with USD 523.4 million in cash, cash equivalents, and marketable securities, reflecting an increase of USD 130 million over the prior year. During the period, 10x Genomics CEO Serge Saxonov noted disciplined execution amid a challenging environment and highlighted strengthening business fundamentals. The company reported expanding impact from its platforms, driven by product innovations and strategic partnerships. 10x Genomics also cited positioning for growth in areas including AI-driven demand, translational research, and emerging clinical opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLgrPxy:1","article_id":"2611970896","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611970896","pubTimestamp":1770930537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"10x Genomics reported revenue of USD 166.03 million for the fourth quarter  of 2025, representing a 1% increase. Gross margin for the quarter was 68%, compared to 67% for the same period in the prior year. For the full year  2025, total revenue was USD 642.82 million. Products and services revenue reached USD 596.69 million in FY 2025, while license and royalty revenue totaled USD 46.14 million. The company ended the year with USD 523.4 million in cash, cash equivalents, and marketable securities, reflecting an increase of USD 130 million over the prior year. During the period, 10x Genomics CEO Serge Saxonov noted disciplined execution amid a challenging environment and highlighted strengthening business fundamentals. The company reported expanding impact from its platforms, driven by product innovations and strategic partnerships. 10x Genomics also cited positioning for growth in areas including AI-driven demand, translational research, and emerging clinical opportunities.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","TXG":"10x Genomics, Inc.","BK4121":"生命科学工具和服务","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"translate_title":"10x Genomics第四季度营收总计1.6603亿美元，增长1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":0.9},"content_text":"10x Genomics Q4 revenue totals USD 166.03 million, up 1 percent\n    \n\n        10x Genomics reported revenue of USD 166.03 million for the fourth quarter (Q4) of 2025, representing a 1% increase. Gross margin for the quarter was 68%, compared to 67% for the same period in the prior year. For the full year (FY) 2025, total revenue was USD 642.82 million. Products and services revenue reached USD 596.69 million in FY 2025, while license and royalty revenue totaled USD 46.14 million. The company ended the year with USD 523.4 million in cash, cash equivalents, and marketable securities, reflecting an increase of USD 130 million over the prior year. During the period, 10x Genomics CEO Serge Saxonov noted disciplined execution amid a challenging environment and highlighted strengthening business fundamentals. The company reported expanding impact from its platforms, driven by product innovations and strategic partnerships. 10x Genomics also cited positioning for growth in areas including AI-driven demand, translational research, and emerging clinical opportunities.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}